Even though the combined use of CTLA-4 inhibitors and PD-1 inhibitors has shown significantly more satisfactory clinical outcomes in melanoma than either alone, little research has been done to identify the miRNA profile signatures that feature the varied clinical outcomes of the combined therapy of ICIs. This evidence concerns the gene CTLA4 and melanoma.